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Summary
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, 
and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological 
options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to 
assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive 
hypertrophic cardiomyopathy.
Methods In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical 
cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 
50 mm Hg or greater and New York Heart Association (NYHA) class II–III symptoms were assigned (1:1) to receive 
mavacamten (starting at 5 mg) or placebo for 30 weeks. Visits for assessment of patient status occurred every 
2–4 weeks. Serial evaluations included echocardiogram, electrocardiogram, and blood collection for laboratory tests 
and mavacamten plasma concentration. The primary endpoint was a 1·5 mL/kg per min or greater increase in peak 
oxygen consumption (pVO2) and at least one NYHA class reduction or a 3·0 mL/kg per min or greater pVO2 increase 
without NYHA class worsening. Secondary endpoints assessed changes in post-exercise LVOT gradient, pVO2, 
NYHA class, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic 
Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore (HCMSQ-SoB). This study is registered 
with ClinicalTrials.gov, NCT03470545.
Findings Between May 30, 2018, and July 12, 2019, 429 adults were assessed for eligibility, of whom 251 (59%) were 
enrolled and randomly assigned to mavacamten (n=123 [49%]) or placebo (n=128 [51%]). 45 (37%) of 123 patients on 
mavacamten versus 22 (17%) of 128 on placebo met the primary endpoint (difference +19·4%, 95% CI 8·7 to 30·1; 
p=0·0005). Patients on mavacamten had greater reductions than those on placebo in post-exercise LVOT gradient 
(–36 mm Hg, 95% CI –43·2 to –28·1; p<0·0001), greater increase in pVO2 (+1·4 mL/kg per min, 0·6 to 2·1; p=0·0006), 
and improved symptom scores (KCCQ-CSS +9·1, 5·5 to 12·7; HCMSQ-SoB –1·8, –2·4 to –1·2; p<0·0001). 34% more 
patients in the mavacamten group improved by at least one NYHA class (80 of 123 patients in the mavacamten 
group vs 40 of 128 patients in the placebo group; 95% CI 22·2 to 45·4; p<0·0001). Safety and tolerability were similar 
to placebo. Treatment-emergent adverse events were generally mild. One patient died by sudden death in the placebo 
group.
Interpretation Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, 
and health status in patients with obstructive hypertrophic cardiomyopathy. The results of this pivotal trial highlight 
the benefits of disease-specific treatment for this condition.
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Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Hypertrophic cardiomyopathy is a myocardial disorder 
characterised by primary left ventricular hypertrophy.1,2 
This complex disease can be broadly defined by patho­
logically enhanced cardiac actin–myosin interac tions, 
with core pathophysiological features that include hyper­
contractility, diastolic abnormalities, and dynamic left 
ventricular outflow tract (LVOT) obstruction.2–4 Patients 
with obstructive hypertrophic cardiomyopathy are often 
symptomatic and can have atrial fibrillation, heart failure, 
and malignant ventricular arrhythmias.2,5 Current treat­
ment for obstructive hypertrophic cardio myopathy focuses 
on symptomatic relief with β blockers, non­dihydro­
pyridine calcium channel blockers, and diso pyramide.6–9 
However, these non­specific agents are often inadequate or 
poorly tolerated,10 do not address the under lying molecular 
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mechanisms of hypertrophic cardio myopathy, and do 
not modify its natural history. Invasive septal reduction 
therapy, including surgical septal myectomy and alcohol 
septal ablation, can effectively help patients with drug­
refractory symptoms,6,7 but carries risks inherent to 
invasive procedures and requires expertise that is not 
universally available.11–13 Thus, developing effective pharma­
cological therapy for obstructive hyper trophic cardio­
myopathy is an important unmet need.
Mavacamten is a first­in­class, small molecule, selective 
allosteric inhibitor of cardiac myosin ATPase specifically 
developed to target the underlying pathophysiology of 
hypertrophic cardiomyopathy by reducing actin–myosin 
cross­bridge formation,14,15 thereby reducing contractility 
and improving myocardial energetics.16 In preclinical 
and early clinical studies, treatment with mavacamten 
successfully relieved LVOT gradients and improved 
parameters of left ventricular filling.15,17–20 In the phase 2, 
open­label PIONEER­HCM study (NCT02842242), 
mavacamten was well tolerated and significantly reduced 
post­exercise LVOT gradients in obstructive hypertrophic 
cardiomyopathy.19 Treatment was also associated with 
improvements in exercise capacity and New York Heart 
Association (NYHA) func tional class. On the basis of 
these results, the pivotal EXPLORER­HCM trial aimed 
to assess the efficacy and safety of mavacamten for 
targeted medical treatment of obstructive hypertrophic 
cardiomyopathy.
Methods
Study design and participants
EXPLORER­HCM was a phase 3, multicentre, randomised, 
double­blind, placebo­controlled, parallel­group trial in 
68 clinical cardiovascular centres in 13 countries (appendix 
p 2). The trial design was published previously.21 Data 
were collected, managed, and analysed by the sponsor 
according to a predefined statistical analysis plan, and 
results were independently validated by the Duke Clinical 
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Research in context
Evidence before this study
The gaps in therapeutic options for hypertrophic 
cardiomyopathy are well recognised, and no pharmacological 
agent is indicated for treatment of the condition (only 
propranolol carries a US Food and Drug Administration 
indication for improving New York Heart Association functional 
class in symptomatic hypertrophic subaortic stenosis based on 
an uncontrolled series of 13 patients). In the absence of 
randomised trials, guideline-recommended pharmacological 
therapy is administered on an empirical basis and includes 
β blockers or non-dihydropyridine calcium channel blockers, 
as well as disopyramide for individuals refractory to first-line 
therapy. Although beneficial for some patients, use of these 
drugs is limited by side-effects, and often does not provide 
optimal control of left ventricular outflow tract (LVOT) 
gradients and symptoms, leaving an unmet burden of disease in 
many patients. We searched PubMed for research articles 
published between database inception and Aug 14, 2020, 
using the terms “hypertrophic cardiomyopathy”, “hypertrophic 
subaortic stenosis”, and “phase 3”, with no language restrictions 
applied. We did not identify any published phase 3 clinical trial 
for pharmacological agents. Several agents, such as perhexiline, 
trimetazidine, ranolazine, eleclazine, spironolactone, valsartan, 
and losartan, have shown no or limited efficacy in other 
prospective trials. In the published phase 2 PIONEER-HCM trial in 
patients with obstructive hypertrophic cardiomyopathy, 
treatment with mavacamten led to improvements in post-
exercise LVOT gradients, exercise capacity, and symptoms, 
and was generally well tolerated, with most adverse effects being 
mild or moderate, self-limiting, and unrelated to the study drug.
Added value of this study
This pivotal phase 3 EXPLORER-HCM trial is the largest placebo-
controlled randomised clinical trial to date in hypertrophic 
cardiomyopathy, to our knowledge. Most patients in the active 
treatment and placebo groups continued to receive currently 
available background hypertrophic cardiomyopathy therapy 
except disopyramide (ie, monotherapy with β blockers or 
non-dihydropyridine calcium channel blockers). The primary 
composite functional endpoint and sequential secondary 
endpoints were designed and discussed with hypertrophic 
cardiomyopathy experts, patients, and regulatory authorities 
to comprehensively assess treatment benefits for obstructive 
hypertrophic cardiomyopathy. The endpoints comprised 
measures of symptoms and functional capacity as well as LVOT 
obstruction and health status. After 30 weeks of treatment with 
mavacamten, there was a significant benefit across the 
composite primary endpoint, its components, and all secondary 
endpoints, as well as relevant improvements in patient-
reported measures and reductions in biomarkers of cardiac wall 
stress and injury. Treatment with mavacamten was generally 
well tolerated and the safety profile was similar to placebo. 
Seven patients on mavacamten (three patients during the 
30-week treatment and four patients at the end of treatment) 
and two on placebo had a transient decrease in left ventri cular 
ejection fraction to less than 50%.
Implications of all the available evidence
Results from this phase 3 trial show significant efficacy of the 
first targeted pharmacological therapy designed specifically to 
address the primary underlying pathophysiological basis of 
obstructive hypertrophic cardiomyopathy. Treatment with 
mavacamten led to clinically meaningful improvements in 
haemodynamic status, functional capacity, and subjective 
wellbeing. An ongoing, long-term extension of the study will 
provide further evidence for clinical benefit and safety of 
mavacamten over 5 years.
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Research Institute (Durham, NC, USA). Analysis outputs 
were provided to the investigators and authors who were 
involved in data interpretation.
The inclusion and exclusion criteria were primarily 
developed to prioritise safety and include a patient 
popula tion adequately representative of real­world symp­
tomatic obstructive hypertrophic cardiomyopathy. Eligible 
patients were aged at least 18 years with a diagnosis of 
obstructive hypertrophic cardiomyopathy (unexplained 
left ventri cular hypertrophy with maximal left ventricular 
wall thickness of ≥15 mm [or ≥13 mm if familial 
hypertrophic cardio myopathy]); peak LVOT gradient at 
least 50 mm Hg at rest, after Valsalva manoeuvre or 
exercise; left ventri cular ejection fraction (LVEF) at 
least 55%; and NYHA class II–III symptoms. Patients 
had to be able to safely perform upright cardio pulmonary 
exercise testing (CPET). Key exclusion criteria included 
a history of syncope or sustained ventricular tachyar­
rhythmia with exercise within 6 months before screening; 
QT interval corrected using Fridericia’s formula more 
than 500 ms; paroxysmal or intermittent atrial fibril lation 
present on screening electrocardiograph; and persistent 
or permanent atrial fibrillation not on anticoagulation 
for 4 weeks or more or not adequately rate­controlled 
within 6 months before screening. Patients who under­
went septal reduction therapy more than 6 months before 
screening were enrolled if otherwise eligible.21 Patients 
were allowed to continue standard hypertrophic cardio­
myopathy medical therapy except disopyramide (for 
safety reasons), including monotherapy with β blockers 
or calcium channel blockers, if dosing remained stable 
for at least 2 weeks before screening and no changes were 
anticipated during the study.
The protocol was approved by site institutional review 
boards at all sites and done in accordance with the 
Declaration of Helsinki and Good Clinical Practice 
guidelines. All patients provided informed consent.
Randomisation and masking
Patients were randomly assigned (1:1) via an interactive 
response system to receive once­daily orally admin­
istered treatment with mavacamten (starting dose 5 mg) 
or placebo for 30 weeks (end of treatment). The trial was 
double­blind, and the principal investigator, site staff 
including the pharmacist, and the patient were masked 
to which study drug was being administered. In add­
ition, the sponsor, the central and core laboratories, 
and clinical site monitors were masked to assigned 
treatment. Mavacamten and matching placebo were 
identical in appearance to preserve the masking. Study 
drug (mavacamten or matching placebo) was labelled 
with a unique identifying number that was assigned to 
a patient through the interactive response system. 
Randomisation was stratified by NYHA class (II or III), 
current β blocker use (yes or no), ergometer type 
(treadmill or bicycle), and consent for cardiovascular 
MRI substudy (yes or no).
Procedures
Mavacamten dose adjustments occurred per a blinded 
dose titration scheme at weeks 8 and 14. Individualised 
doses of 2·5, 5, 10, or 15 mg were ultimately administered 
orally to achieve target reduction in LVOT gradient less 
than 30 mm Hg and a mavacamten plasma concentra tion 
between 350 ng/mL and 700 ng/mL.21 Prespecified criteria 
for temporary discontinuation of study drug, including 
LVEF less than 50%, are described in the appendix (p 3).
Patients were evaluated every 2 weeks or 4 weeks 
during the 30­week treatment period. CPET and post­
exercise transthoracic echocardiography were done at 
screening and week 30. Resting transthoracic echocardio­





Age, years 58·5 (12·2) 58·5 (11·8)
Sex
Women 57 (46%) 45 (35%)
Men 66 (54%) 83 (65%)
Race
White 115 (93%) 114 (89%)
Black or African American 1 (1%) 5 (4%)
Native American or Alaskan Native 0 1 (1%)
Asian 4 (3%) 2 (2%)
Unknown 3 (2%) 6 (5%)
Region
USA 53 (43%) 55 (43%)
Spain 17 (14%) 16 (13%)
Poland 16 (13%) 16 (13%)
Other* 37 (30%) 41 (32%)
Hypertrophic cardiomyopathy genetic testing 
performed
90 (73%) 100 (78%)
Pathogenic or likely pathogenic hypertrophic 
cardiomyopathy gene variant
28/90 (31%) 22/100 (22%)
Medical history
Family history of hypertrophic cardiomyopathy 33 (27%) 36 (28%)
Atrial fibrillation 12 (10%) 23 (18%)
Septal reduction therapy 11 (9%) 8 (6%)
Hypertension 57 (46%) 53 (41%)
Hyperlipidaemia 27 (22%) 39 (30%)
Coronary artery disease 12 (10%) 6 (5%)
Obesity 15 (12%) 14 (11%)
Type 2 diabetes 6 (5%) 7 (6%)
Asthma 17 (14%) 11 (9%)
Chronic obstructive pulmonary disease 2 (2%) 3 (2%)
Background hypertrophic cardiomyopathy therapy
β blocker 94 (76%) 95 (74%)
Calcium channel blocker 25 (20%) 17 (13%)
Implantable cardioverter-defibrillator 27 (22%) 29 (23%)
Body-mass index, kg/m² 29·7 (4·9) 29·2 (5·6)
Heart rate, beats per min 63 (10·1) 62 (10·6)
Systolic blood pressure, mm Hg 128 (16·2) 128 (14·6)
(Table 1 continues on next page)
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determination of mavacamten plasma concentration 
were done serially every 2–4 weeks across 12 visits 
throughout the study. Results were determined by central 
core laboratories masked to treatment assignment.21 A 
60­gene hyper trophic cardiomyopathy genetic testing 
panel (if consent provided) was also done.
Outcomes
The primary endpoint was a composite to assess clinical 
response at week 30 compared with baseline, defined as 
a 1·5 mL/kg per min or greater increase in pVO2 and at 
least one NYHA class reduction; or a 3·0 mL/kg per min 
or greater improvement in pVO2 and no worsening of 
NYHA class.
Secondary endpoints were change from baseline to 
week 30 in post­exercise LVOT gradient, pVO2, proportion 
of patients with at least one NYHA class improvement, 
and mea sures of patient­reported outcomes, including 
Kansas City Cardiomyopathy Questionnaire­Clinical 
Summary Score (KCCQ­CSS) and Hypertrophic Cardio­
myopathy Symp tom Questionnaire Shortness­of­Breath 
(HCMSQ­SoB) subscore.21 All assessments for secondary 
endpoints were performed and type I error was controlled 
in hierarchical order (sequence as indicated above) upon 
achieving significance in the primary endpoint (with two­
tailed p<0·05 required to proceed).
Additional prespecified exploratory endpoints assessed 
complete response (all LVOT gradients less than 30 mm Hg 
and NYHA class I); proportion of patients with improve­
ment in LVOT gradients; and serum concen trations of 
N­terminal pro B­type natriuretic peptide (NT­proBNP) and 
high­sensitivity cardiac troponin I (hs­cTnI). Prespecified 
safety endpoints included fre quency and severity of treat­
ment­emergent adverse events and serious adverse events.
Statistical analysis
The study was designed to randomly assign a minimum 
of 220 patients. The sample size was estimated to 
provide 96% power to detect a 25% difference between 
treatment groups for the primary endpoint, at a two­
sided p<0·05.21
All randomly assigned patients received at least one 
dose of study drug. Efficacy and safety analyses were 
based on this population, and efficacy analyses followed 
the intention­to­treat principle. Missing data were not 
imputed unless prespecified in the statistical analysis 
plan. The missing NYHA classes at week 30 were 
imputed with the week 26 value, if available, in the case 
of the primary endpoint and NYHA response. Patients 
with a non­evaluable primary endpoint and NYHA 
secondary endpoint were considered as non­responders, 
whereas LVOT gradient and pVO2 were analysed with all 
available data without imputation, and patient­reported 
outcomes were analysed with all available data using 
mixed­effect model repeated measure, which implicitly 
handles the missing data in the patients that have 
baseline and one or more post­baseline values in the 
analysis (appendix pp 3–4). The primary efficacy end­
point and improvement in NYHA class were analysed 
with the Cochran–Mantel–Haenszel test for stratified 
categorical data. Continuous variables in secondary 
efficacy endpoints were compared between treatment 
groups by ANCOVA or by mixed­effect model repeated 
measure. Efficacy was also assessed in prespecified 
subgroups based on baseline demographic and disease 
characteristics. Safety data were analysed with descriptive 
statistics without statistical inference. SAS version 9.4 
was used for statistical analyses. The statistical analysis 
plan and further details are provided in the appendix 
(pp 3–4). The trial was overseen by a steering committee, 
independent data monitoring committee, and a clinical 
event adjudication committee. This study is registered 
with ClinicalTrials.gov, NCT03470545.
Role of the funding source
Co­authors employed by the funder were involved in 
study design, statistical analysis, data interpretation, and 
review of the manuscript, in collaboration with academic 
coauthors. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
From May 30, 2018, to July 12, 2019, 429 adults with 





(Continued from previous page)
Diastolic blood pressure, mm Hg 75 (10·8) 76 (9·9)
NYHA functional class II 88 (72%) 95 (74%)
NYHA functional class III 35 (28%) 33 (26%)
pVO2, mL/kg per min 18·9 (4·9) 19·9 (4·9)
NT-proBNP, geometric mean, ng/L (CV%)† 777 (136) 616 (108)
High-sensitivity cardiac troponin I, geometric mean, 
ng/L (CV%)‡
12·5 (208) 12·5 (373)
Echocardiographic parameters
LVEF, % 74 (6) 74 (6)
Maximum left ventricular wall thickness, mm 20 (4) 20 (3)
LVOT gradient, rest, mm Hg 52 (29) 51 (32)
LVOT gradient, Valsalva, mm Hg 72 (32) 74 (32)
LVOT gradient, post-exercise, mm Hg§ 86 (34) 84 (36)
Left atrial volume index, mL/m²¶ 40 (12) 41 (14)
Left atrial diameter, mm|| 42 (5) 42 (6)
Data are mean (SD), n (%), or n/N (%), unless otherwise indicated. LVEF=left ventricular ejection fraction. LVOT=left 
ventricular outflow tract. NYHA=New York Heart Association. NT-proBNP=N-terminal pro B-type natriuretic peptide. 
pVO2=peak oxygen consumption. *Other comprised Israel, Germany, France, Czech Republic, Denmark, Netherlands, 
Portugal, Italy, Belgium, and the UK (ordered by number of patients). †Data missing for three patients in the 
mavacamten group and two patients in the placebo group. The variation number (CV%) is the coefficient of variation, 
which is defined as the ratio of the SD to the mean. ‡Data missing for three patients in the mavacamten group and 
nine patients in the placebo group. §Data missing for one patient in the mavacamten group and one patient in the 
placebo group. ¶Data missing for one patient in the mavacamten group. ||Data missing for five patients in each group. 
Table 1: Baseline characteristics
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for eligi bility, of whom 251 (59%) were enrolled and 
randomly assigned (1:1) to mavacamten (n=123 [49%]) or 
placebo (n=128 [51%]; appendix p 5). Enrolled patients 
showed the expected features of obstructive hypertrophic 
cardiomyopathy cohorts in terms of mean left ventricular 
wall thickness, proportion with a positive family history 
for the con dition, and proportion with an implantable 
cardioverter­defibrillator (table 1). Mean age of partici­
pants was 58·5 years (SD 11·9), with 21% of patients 
aged younger than 50 years, 45% aged 50–64 years, and 
34% aged 65 years or older. Baseline characteristics were 
balanced between groups, except for a smaller proportion 
of men, a smaller proportion of patients with a history 
of atrial fibrillation, and higher baseline NT­proBNP 
concentration in the mavacamten group compared with 
placebo (table 1). Most patients (n=183 [73%]) had NYHA 
class II symptoms at baseline, and almost all (n=231 [92%]) 
were on background β blocker or calcium channel blocker 
therapy—only four patients in the mavacamten group 
and 16 in the placebo group were not on background 
hypertrophic cardiomyopathy therapy. Almost all patients 
were compliant and maintained their back ground hyper­
trophic cardiomyopathy therapy unchanged throughout 
the study or required minor adjustments (16 patients in 
the mavacamten group and ten patients in the placebo 
group adjusted their dose of β blocker therapy). Nineteen 
patients had previous septal reduction therapy (11 patients 
in the mavacamten group and eight patients in the 
placebo group).
Overall, 244 (97%) patients completed treatment. Five 
patients discontinued treatment prematurely (appendix 
p 5); three due to adverse events (two on mavacamten 
[atrial fibrillation and syncope], one on placebo [sudden 
death]); and two patients withdrew (one on mavacamten, 
one on placebo). No patients were lost to follow­up.
At the end of treatment, 45 (37%) of 123 patients on 
mavacamten met the primary endpoint, compared with 
22 (17%) of 128 on placebo (+19·4%, 95% CI 8·7–30·1; 
p=0·0005; table 2). Furthermore, 25 (20%) patients on 
mavacamten had both at least a 3·0 mL/kg per min 
increase in pVO2 and at least one class improvement 
in NYHA class, versus ten (8%) on placebo (differ­
ence +12·5%, 95% CI 4·0–21·0). Baseline demographic 
and disease characteristics, and key efficacy and safety 
parameters for patients with or without missing data 
in KCCQ­CSS or HCMSQ­SoB revealed no consistent 
pattern of differences between those groups. Further­
more, worst case scenario analyses showed that, even after 
imputing the missing data with unfavourable results 
toward the mavacamten group, the estimated treatment 
effects on KCCQ­CSS or HCMSQ­SoB remained signifi­
cant (p<0·05). These analyses support the notion that the 
missing at random assumption was not violated. Data in 
table 2 reflect the prespecified analyses.
Mavacamten treatment was associated with a signifi­
cant improvement in all secondary endpoints compared 
with placebo (table 2), with patients showing reduced 
LVOT gradient, increased pVO2, and improved symp toms 
as assessed by physicians (NYHA class) or by themselves 
(patient­reported outcomes). Peak post­exercise LVOT 
gradient decreased from 86 mm Hg (95% CI 79·5 to 91·8) 
to 38 mm Hg (32·3 to 44·0) with mavacamten, whereas 
for placebo the change was from 84 mm Hg (78·4 to 91·0) 
to 73 mm Hg (67·2 to 79·6; figure 1A), showing a greater 
mean reduction by 35·6 mm Hg with mavacamten 





Difference* (95% CI), p value
Primary endpoint†
Either ≥1·5 mL/kg per min increase in pVO2 with ≥1 NYHA class 
improvement or ≥3·0 mL/kg per min increase in pVO2 with no worsening 
of NYHA class
45 (37%) 22 (17%) 19·4 (8·7 to 30·1; p=0·0005)
≥1·5 mL/kg per min increase in pVO2 with ≥1 NYHA class improvement 41 (33%) 18 (14%) 19·3 (9·0 to 29·6)
≥3·0 mL/kg per min increase in pVO2 with no worsening of NYHA class 29 (24%) 14 (11%) 12·6 (3·4 to 21·9)
Both ≥3·0 mL/kg per min increase in pVO2 and ≥1 NYHA class 
improvement
25 (20%) 10 (8%) 12·5 (4·0 to 21·0)
Secondary endpoints‡
Post-exercise LVOT gradient change from baseline to week 30, mm Hg –47 (40), n=117 –10 (30), n=122 –35·6 (–43·2 to –28·1; p<0·0001)
pVO2 change from baseline to week 30, mL/kg per min 1·4 (3·1), n=120 –0·1 (3·0), n=125 1·4 (0·6 to 2·1; p=0·0006)
≥1 NYHA class improvement from baseline to week 30§ 80 (65%) 40 (31%) 34% (22 to 45; p<0·0001)
Change from baseline to week 30 in KCCQ-CSS§ 13·6 (14·4), n=92 4·2 (13·7), n=88 9·1 (5·5 to 12·7; p<0·0001)
Change from baseline to week 30 in HCMSQ-SoB§ –2·8 (2·7), n=85 –0·9 (2·4), n=86 –1·8 (–2·4 to –1·2; p<0·0001)
Data are n (%) or mean (SD). HCMSQ-SoB=Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore. KCCQ-CSS=Kansas City Cardiomyopathy 
Questionnaire-Clinical Symptom Score. LVOT=left ventricular outflow tract. pVO2=peak oxygen consumption. NYHA=New York Heart Association. *Model estimated least-square 
mean differences were reported for continuous variables. †Patients with a non-evaluable primary endpoint and NYHA secondary endpoint were considered as non-responders. 
The response rates were calculated with the N value as the denominator. ‡N was the number analysable for secondary endpoints based on availability of both baseline and week 
30 values. §Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post-hoc analyses compared the reasons for missing data. 
Table 2: Primary and secondary endpoints
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In parallel, patients on mavacamten showed a greater 
mean increase in pVO2 by 1·4 mL/kg per min than 
those on placebo (95% CI 0·6 to 2·1; p=0·0006). Also, 
80 (65%) of 123 patients given mavacamten had at least 
one NYHA class improvement versus 40 (31%) of 128 on 
placebo (difference 33·8%, 95% CI 22·2 to 45·4; 
p<0·0001). The proportion of patients who reached 
NYHA class I status was 50% (61 of 123) with 
Figure 1: LVOT gradients, LVEF, and cardiac biomarkers
Mean post-exercise LVOT gradient over time (A), LVEF (B), resting LVOT gradient (C), and Valsalva LVOT gradient (D). Geometric mean over time is shown for 
NT-proBNP (E) and hs-cTnI (F). Error bars are 95% CIs. The dashed lines represent the threshold for guideline-based invasive intervention (LVOT gradient >50 mm Hg) 
in A and D, the threshold for guideline-based diagnosis of obstruction (LVOT gradient <30 mm Hg) in C, and the protocol threshold for temporary discontinuation 
(LVEF <50%) in B. hs-cTnI=high-sensitivity cardiac troponin I. LVEF=left ventricular ejection fraction. LVOT=left ventricular outflow tract. NT-proBNP=N-terminal pro 

















0 304 6 12 18 22 26
72·2 71·8 69·7 70·3 70·9 70·9 70·2













0 304 6 12 18 22 260 304 6 12 18 22 26
51·7
25·7 23·2





















































































































































































































www.thelancet.com   Published online August 29, 2020   https://doi.org/10.1016/S0140-6736(20)31792-X 7
mavacamten and 21% (27 of 128) with placebo (figure 2). 
Mavacamten treat ment was also associated with 
improved patient­reported out comes. Both KCCQ­CCS 
(positive change better) and HCMSQ­SoB (negative 
change better) scores improved more with mavacamten 
than with placebo (KCCQ­CCS +9·1, 95% CI 5·5 to 12·7; 
HCMSQ­SoB −1·8, −2·4 to −1·2; p<0·0001 for both).
Patients given mavacamten showed rapid and 
sustained improvement in resting and Valsalva LVOT 
gradients compared with placebo (figure 1C, D). 
Complete response (defined as reduction in all LVOT 
gradients to less than 30 mm Hg and reaching NYHA 
class I) was met by 32 (27%) of 117 patients on 
mavacamten versus one (1%) of 126 on placebo (+26·6%, 
95% CI 18·3 to 34·8; table 3). Mavacamten treatment 
relieved LVOT obstruction (post­exercise gradient 
<30 mm Hg) in 50% more (absolute difference) patients 
(64 [57%] of 113 vs eight [7%] of 114, 95% CI 39·3 to 
59·9), and reduced the gradient to less than the stan­
dard threshold for invasive septal reduction therapy 
(<50 mm Hg) in 53% more (absolute difference) patients 
(75 [74%] of 101 vs 22 [21%] of 106, 95% CI 42·0 to 65·0) 
compared with placebo (table 3). In contrast to the sharp 
decline in LVOT gradients, changes in baseline systolic 
function associated with mavacamten were small. 
Mean reduction in LVEF was –3·9%, versus –0·01% 
with placebo (difference –4·0%, 95% CI –5·5 to –2·5; 
figure 1B). Decreases in cardiac biomarkers were sim­
ilarly rapid and sustained, parallel to the haemo dynamic 
changes observed (figure 1E, F). At week 30 compared 
with baseline, the reduction in NT­proBNP after 
mavacamten treatment was 80% greater than for pla­
cebo (proportion of geometric mean ratio between the 
two groups 0·202, 95% CI 0·169 to 0·241); reduction 
in hs­cTnI was 41% greater for mavacamten than for 
placebo (0·589, 0·500 to 0·693).
Patients given mavacamten showed consistent benefit 
for the primary endpoint across prespecified sub­
groups. We further examined the subgroups of patients 
receiving versus not receiving background β blockade 
therapy. Importantly, most patients not using β blockers 
were prescribed non­dihydropyridine calcium channel 
blockers, with very few patients in each treatment group 
taking neither (four of 123 in the mavacamten group 
and 16 of 128 in the placebo group were not on any 
background hypertrophic cardiomyopathy therapy). In 
patients without concomitant β blockade, the effect 
was greater (n=29 on mavacamten, n=33 on placebo; 
difference 52·6%, 95% CI, 32·9 to 72·2) versus those on 
β blockers (n=94 on mavacamten, n=95 on placebo; 
difference 8·7%, –3·6 to 21·1), and this observation 
remained in a multivariable model after adjusting for 
baseline covariates (figure 3A). As expected, the mean 
peak heart rate with exercise tended to be lower for the 
subgroup of patients using β blockers (119 beats per min 
at baseline) compared with those not using β blockers 
(138 beats per min at baseline). Similarly, mean pVO2, a 
component of the primary endpoint, was lower for the 
β blocker subgroup at baseline, and the mean change at 
week 30 in pVO2 was also observed to be lower 
(1·1 [SD 3·1] mL/kg per min) for patients using β blockers 
compared with for those who were not using β blockers 
(2·2 [3·0] mL/kg per min). Conversely, heart rate 
independent parameters of CPET, including the minute 
ventilation to carbon dioxide production (VE/VCO2) 
slope, showed improvements with mavacamten treat­
ment compared with placebo irrespective of β blocker 
use. The VE/VCO2 slope change from baseline at week 
30 was –2·5 (95% CI –3·7 to –1·4) in the β blocker 
subgroup, –2·5 (–4·8 to –0·2) in the non­β blocker 
subgroup, and –2·6 (–3·6 to –1·5) in the overall cohort. 
Rates of improvement by at least one NYHA class with 
mavacamten treatment were also similar among patients 
receiving β blockers and those who were not (both 65%). 
Furthermore, all secondary endpoints, including change 
in LVOT gradient (figure 3B), showed consistent benefit 
Mavacamten group Placebo group Difference (95% CI)
Complete response* 32/117 (27%) 1/126 (1%) 26·6 (18·3–34·8)
Post-exercise LVOT peak gradient 
<50 mm Hg†
75/101 (74%) 22/106 (21%) 53·5 (42·0–65·0)
Post-exercise LVOT peak gradient 
<30 mm Hg‡
64/113 (57%) 8/114 (7%) 49·6 (39·3–59·9)
Data are n/N (%), unless otherwise indicated. LVOT=left ventricular outflow tract. *Defined as New York Heart 
Association class I and all LVOT peak gradients less than 30 mm Hg (post exercise, resting, and Valsalva). †Threshold 
for guideline-based invasive intervention. Only patients with baseline post-exercise LVOT peak gradient of at least 
50 mm Hg were assessed. ‡Threshold for guideline-based diagnosis of obstruction. Only patients with baseline 
post-exercise LVOT peak gradient of at least 30 mm Hg were assessed.
Table 3: Key exploratory efficacy endpoints
Figure 2: NYHA functional class
Percentage of patients who had NYHA class I, II, or III at baseline, after 14 weeks and 30 weeks of treatment, for the 
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Figure 3: Forest plot of 
treatment effect on primary 
endpoint and post-exercise 
LVOT gradient by subgroups
(A) Mean difference in 
patients meeting the primary 
endpoint. The dashed vertical 
line (overall effect) represents 
the between-treatment group 
difference in the overall study 
cohort (19%), and the solid 
vertical line (no effect) 
indicates no difference 
between treatment groups. 
(B) Mean difference in LVOT 
gradient reduction between 
mavacamten and placebo. 
The dashed vertical line 
(overall effect) represents the 
between-treatment group 
difference in the overall study 
cohort (−36 mm Hg). The solid 
vertical line indicates findings 
if there was no difference 
between treatment groups. 
Patients with a non-evaluable 
primary endpoint were 
considered as non-responders. 
HCM=hypertrophic 
cardiomyopathy. LVEF=left 
ventricular ejection fraction. 
NT-proBNP=N-terminal 
pro-B-type natriuretic peptide. 
NYHA=New York Heart 
Association. 
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for mavacamten across pre specified subgroups, irres­
pective of β blocker use.
Treatment­emergent adverse events were generally mild 
(table 4, appendix p 6). 11 serious adverse events were 
reported by ten (8%) patients on mavacamten versus 
20 events reported by 11 (9%) on placebo (table 4). Serious 
cardiac adverse events occurred in four patients in the 
mavacamten group (two atrial fibrillation, two stress 
cardiomyopathy); one of these presented during a study 
visit and simultaneously triggered a temporary discon­
tinuation for LVEF less than 50% (appendix p 7). There 
were also four serious cardiac adverse events in the placebo 
group (three atrial fibrillation, one atrial fibrillation with 
con gestive heart failure). One patient in the placebo group 
experienced sudden death. No serious events of heart 
failure occurred in the mavacamten group. Overall, 
nine patients (seven on mavacamten and two on placebo) 
had a transient decrease in LVEF to less than 50%. 
Five patients (three on mavacamten, two on placebo) had 
protocol­driven temporary treatment discon tinuation for 
LVEF less than 50% during the 30­week treatment period 
(median LVEF 48%, range 35–49; appendix p 7). LVEF 
normalised in all patients, and they resumed treatment 
and completed the study. Four additional patients on 
mavacamten had LVEF less than 50% (range 48–49) at 
week 30 (end­of­treatment visit). LVEF was confirmed to 
recover to baseline after the 8­week washout period in 
three patients. The fourth patient had a procedural 
complication and severe LVEF drop following atrial 
fibrillation ablation during the wash out period, followed by 
partial recovery (to LVEF 50%). Six patients (three on 
mavacamten, three on placebo) met predefined criteria for 
changes in QT interval corrected using Fridericia’s formula 
and underwent temporary discontinuation followed by 
resumption and completion of treat ment. There were no 
temporary discontinuations for mavacamten plasma 
concentration greater than 1000 ng/mL.
There were no treatment differences noted on 
laboratory values, electrocardiographs, or vital signs at 
rest, including no significant changes in heart rate 
and blood pressure from baseline to week 30 with 
mavacamten. Continuous cardiac monitoring with a 
48­h Holter was done at baseline, week 12, and week 26. 
No significant differences were seen during treatment 
between groups in the number of patients with any atrial 
fibrillation detected (eg, in each group there were two at 
week 12 and four at week 26). There were similar numbers 
of patients with episodes of non­sustained ventricular 
tachycardia detected in each group and at each timepoint 
(eg, 36 [31%] of 117 in the mavacamten group vs 35 [29%] 
of 122 in the placebo group at baseline; 26 [26%] of 99 in 
the mavacamten group vs 33 [34%] of 96 in the placebo 
group at week 12; and 36 [32%] of 113 in the mavacamten 
group vs 38 [33%] of 117 in the placebo group at week 26). 
The summary of episodes per patient at each timepoint 
showed 1·5–2·0 times more episodes in patients on 
placebo compared with those on mavacamten.
Discussion
In this phase 3 trial in patients with symptomatic 
obstructive hypertrophic cardiomyopathy, treatment with 
mavacamten, a first­in­class cardiac myosin inhibitor, was 
well tolerated and superior to placebo for all primary 
and secondary endpoints. Mavacamten treatment was 
effective in reducing LVOT gradients and improving 
symptoms, exercise performance, and health status in a 
patient population representative of that encountered in 
real­world clinical practice. Significantly more patients 
treated with mavacamten met the primary endpoint that 
used both objective (pVO2) and subjective (NYHA class) 
assessments of functional capacity and symptoms. Spe­
cifi cally, the proportion of participants improving at least 
one NYHA class was 34% greater and the proportion 
meeting both primary endpoint components (at least 
3·0 mL/kg per min pVO2 increase and at least one 
NYHA class improvement) was 13% greater than 
placebo. Findings were consistent across all secon dary 
efficacy endpoints. Furthermore, complete response, 
defined as a reduction in all LVOT gradients to less than 
30 mm Hg and reaching NYHA class I, was met in 
27% of patients given mavacamten and less than 1% of 
patients on placebo, showing that mavacamten might be 
capable of achieving marked relief of symp toms and 





Patients with ≥1 treatment-
emergent adverse event
108 (88%) 101 (79%)
Total number of serious adverse 
events
11 20
Patients with ≥1 serious adverse 
event
10 (8%) 11 (9%)
Atrial fibrillation 2 (2%) 4 (3%)
Syncope 2 (2%) 1 (1%)
Stress cardiomyopathy 2 (2%) 0
Sudden death 0 1 (1%)
Transient ischaemic attack 0 1 (1%)
Cardiac failure congestive 0 1 (1%)
Diverticulitis 1 (1%) 0
Viral gastroenteritis 0 1 (1%)
Urinary tract infection 0 2 (2%)
Infection 1 (1%) 0
Rheumatoid arthritis 0 1 (1%)
Contusion 1 (1%) 0
Forearm fracture 1 (1%) 0
Dehydration 0 1 (1%)
Vocal cord polyp 0 1 (1%)
Cholesteatoma 0 1 (1%)
Prostate cancer 0 1 (1%)
Data are n (%). 
Table 4: Summary of treatment-emergent adverse events and serious 
adverse events
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hyper trophic cardiomyopathy with severe symptoms 
who are eligible for septal reduction therapy, the 
VALOR­HCM study (NCT04349072) will investigate the 
ability of mavacamten to provide a non­invasive treatment 
option, reducing the need for surgical or percutaneous 
procedures.
Patient­reported outcome assessments using KCCQ­
CSS and the novel HCMSQ­SoB, specifically designed 
to evaluate symptomatic burden in patients with hyper­
trophic cardiomyopathy, showed a favourable effect 
of mavacamten on subjective wellbeing. Notably, the 
improvement seen in KCCQ­CSS scores is several times 
higher than that observed in heart failure drug trials 
from the past few years and is nearly half of that achieved 
with placement of a left ventricular assist device for end­
stage heart failure.22,23 Clinical benefit was sustained, 
achieved in addition to treatment with β blockers or 
calcium antagonists, and accompanied by a reduction 
in serum NT­proBNP and hs­cTnI concentrations, two 
predictors of long­term outcome in hypertrophic cardio­
myopathy.24–26 Similar decreases in cardiac biomarkers 
were reported in the MAVERICK­HCM study in patients 
with non­obstructive disease, suggesting that gradient 
reduction might only partly explain the benefit observed 
in EXPLORER­HCM.20 These effects require further 
investigation in a translational setting.16,18
Benefit from mavacamten extended across most pre­
specified subgroups. Not unexpectedly, patients receiving 
concomitant β blockers displayed less of an effect on the 
composite primary endpoint, which includes pVO2, 
compared with those not on β blockers. We do not believe 
that the use of β blockers attenuates the primary 
mechanism by which mavacamten works, as is evident by 
the extent of gradient reduction and other improvements 
observed. Rather, the observed effect on the primary 
endpoint might be related to the well established heart 
rate limitations on CPET perfor mance.27,28 Indeed, the 
mean peak heart rate with exercise tended to be lower 
for the subgroup of patients on β blockers compared 
with those not on β blockers. Improvements in mean 
pVO2 were smaller for patients receiving versus not 
receiving background β blockers. However, the change 
in VE/VCO2 slope, a heart­rate independent CPET 
parameter associated with cardiac output,29 showed 
similar improvements with mavacamten versus placebo 
regardless of β blocker use, and where the starting mean 
VE/VCO2 slope for each was at levels associated with 
elevated risk for mortality in patients with chronic heart 
failure (eg, 33–35). In terms of haemodynamic status, 
symptoms, and general wellbeing, as well as reductions 
in biomarkers of cardiac wall stress and injury (outcomes 
and assessments not captured by CPET performance), 
patients on background β blockers benefited the same as 
those not on β blockers. Further detailed analyses of this 
finding will be pursued in a future study.
Mavacamten was generally well tolerated, whether 
used with β blockers or calcium channel blockers, or in 
those with previous unsuccessful septal reduction 
therapy, or as monotherapy in a small number of 
patients. Only modest reductions in mean global left 
ventricular systolic func tion were observed, with seven 
patients on mavacamten (four patients at the end of 
treatment) developing LVEF less than 50%, which 
normalised after temporary inter ruption of therapy in all 
patients and did not affect study completion. Otherwise, 
the safety profile of mavacamten was similar to that of 
placebo. Studies are ongoing to assess the long­term 
efficacy and safety of mavacamten over 5 years (MAVA­
LTE; NCT03723655).
Study limitations included the exclusion of patients on 
disopyramide and patients with severe (NYHA class IV) 
symptoms. Both populations will be examined in the 
VALOR­HCM study. Furthermore, younger patients 
(<50 years) and those who were not white had low 
representation in this study.
In conclusion, in this first positive randomised phase 3 
trial in patients with obstructive hypertrophic cardio­
myopathy, mavacamten treatment improved functional 
capacity, LVOT gradient, symptoms, and key aspects of 
health status. The results of this pivotal trial highlight the 
benefits of disease­specific treatment in hypertrophic 
cardiomyopathy.
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